Neoadjuvant and adjuvant therapy for early-stage breast cancer Research ... of adjuvant endocrine therapy are recommended to receive endocrine therapy alone or endocrine therapy plus targeted ...

A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain high-risk breast cancer settings.

"Today, many people diagnosed with HR+/HER2- early breast cancer in Europe lack options beyond endocrine therapy to help ... Kisqali® (ribociclib) is a selective cyclin-dependent kinase inhibitor ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Mabel Mardones, MD, Rocky Mountain Cancer Centers, discusses the future of HR+/HER2– breast cancer treatment, focusing on the importance of biomarkers and the potential of SIRDs to improve patient ...

EMA's CHMP issued a positive opinion for Novartis' Kisqali for high-risk early breast ... Kisqali plus endocrine therapy (ET), compared to ET alone, lowered the risk of cancer recurrence by ...

Erika Hamilton, MD, discusses how to approach treatment after progression on first-line therapy and hormone receptor-positive breast cancer.

Erika Hamilton, MD, director of Breast Cancer Research at the Sarah Cannon Research Institute, discusses how to approach treatment after progression on first-line therapy and hormone receptor-positive ...

Among the many impactful sessions, a symposium titled ‘Incorporating Novel Treatment Insights for Estrogen Receptor-Positive (ER+) Early Breast Cancer Patients’ garnered particular attention.

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer ... Kisqali plus endocrine therapy (ET), compared to ET alone, lowered the risk of cancer recurrence by 25.1 ...

Recommendation is based on the Phase III NATALEE trial, where Kisqali added to endocrine therapy (ET) significantly reduced the risk of recurrence by 25% versus ET alone across a broad population of ...